Shares of Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) have received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $17.33.
Several equities research analysts recently weighed in on QNRX shares. Canaccord Genuity Group initiated coverage on Quoin Pharmaceuticals in a research note on Monday, October 19th. They issued a “buy” rating and a $18.00 price target on the stock. Lake Street Capital initiated coverage on Quoin Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “buy” rating and a $20.00 price objective for the company. Weiss Ratings upgraded shares of Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, November 12th. BTIG Research assumed coverage on shares of Quoin Pharmaceuticals in a research report on Monday, October 12th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Wall Street Zen lowered shares of Quoin Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 15th.
Get Our Latest Analysis on Quoin Pharmaceuticals
Insider Buying and Selling at Quoin Pharmaceuticals
In other Quoin Pharmaceuticals news, CFO Sally Lawlor bought 10,244 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was acquired at an average price of $4.88 per share, with a total value of $49,990.72. Following the completion of the purchase, the chief financial officer owned 10,684 shares of the company’s stock, valued at approximately $52,137.92. This trade represents a 2,328.18% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Anthony Culverwell bought 6,146 shares of the stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $4.88 per share, with a total value of $29,992.48. Following the completion of the acquisition, the director directly owned 40,364 shares of the company’s stock, valued at approximately $196,976.32. The trade was a 17.96% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 57,370 shares of company stock worth $279,966. Insiders own 7.54% of the company’s stock.
Institutional Investors Weigh In On Quoin Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC purchased a new position in Quoin Pharmaceuticals in the 3rd quarter worth approximately $1,077,000. AIGH Capital Management LLC lifted its position in Quoin Pharmaceuticals by 237.5% in the 3rd quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock valued at $1,077,000 after acquiring an additional 166,234 shares in the last quarter. Finally, SummitTX Capital L.P. boosted its stake in Quoin Pharmaceuticals by 54.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock valued at $662,000 after purchasing an additional 35,505 shares during the last quarter. 8.63% of the stock is owned by hedge funds and other institutional investors.
Quoin Pharmaceuticals Stock Performance
Shares of Quoin Pharmaceuticals stock opened at $3.36 on Friday. The business has a 50 day moving average of $4.71 and a 200 day moving average of $5.69. Quoin Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $23.50.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.52) by $0.55. As a group, equities research analysts forecast that Quoin Pharmaceuticals will post -7.45 EPS for the current fiscal year.
Quoin Pharmaceuticals Company Profile
Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.
Featured Stories
- Five stocks we like better than Quoin Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
